Yazar "Şen H.S." seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • [ X ]
    Öğe
    Neurofibromatosis and pleural neurofibroma: Case report
    (Logos Medical Publishing, 2011) Şen H.S.; Aydin A.; Abakay A.; Şenyi?it A.
    There is various pulmoner attacks of neurofibromatosis. We presented a neurofibromatosis case with pleural lesion in this study. Fourty four years old male patient. There is a lot of dermal nodules in different sides of his body since childhood. Thorax and abdominal Computed Tomography (CT) has taken. There was a noduler lesion in left lung lower lobe superior segment. It was 43*22 mm size and spurred to pleura. Routine examinations, tumoral markers, fiberoptics bronchoscopy, respiratory function tests and carbon monoxide diffusion capacity test were assessed in normal limits. One biopsy material has taken from dermal lesion. Dermal biopsy result was neurofibrom. After three mounths there was not any difference in lesion at control Thorax CT. The pleural lesion considered as thoracic neurofibroma. There is different pleuropulmoner lesions in neurofibromatosis patients. When we detect pleural mass in neurofibromatosis cases, we must think neurofibrom originated from primer disease in seperator diagnose.
  • [ X ]
    Öğe
    An overview of thrombolytic treatment for pulmonary embolism: A single Centre experience
    (Acta Medica Mediterranea, 2014) Şen H.S.; Abakay Ö.; Sezgi C.; Yilmaz S.; Taylan M.; Kaya H.; Tanrikulu A.C.
    Introduction: A massive pulmonary embolism (MPE) has a poor prognosis and high mortality. Thrombolytic therapy is preferred in patients with life-threatening symptoms such as hypotension, cardiogenic shock, and right ventricular failure due to the risk of severe bleeding. Materials and methods: This is a retrospective analysis of patients who were hospitalized with the diagnosis of pulmonary embolism (PE) and given thrombolytic therapy in the chest diseases clinic of a tertiary university hospital between January 2008 and November 2013. Results: The subjects' mean age was 59.54 ± 13.76 years. Fourteen of 39 patients who were treated with thrombolytic therapy were male (35.89%) and 25 (64.10%) were female. The symptoms experienced by the patients included dyspnea in 39 patients, chest pain in 35 patients, hemoptysis in 6 patients, syncope in 13 patients and cough in 10 patients. Risk factors were advanced age (> 60 years) in 19, immobilization in 19, malignancy in 3, major surgery in 11 patients. The in-hospital mortality analysis showed that 32 patients were discharged and 7 patients died. Four patients died from their pulmonary embolism and 3 patients died because of a major bleeding complication. Conclusions: Pulmonary embolism is a disease that may lead to death within hours secondary to acute right heart failure. Early diagnosis and treatment can be life saving. Thrombolytic therapy has been shown to improve hemodynamic parameters in the early period post-PE. An increased risk of bleeding is one of the most important drawbacks of thrombolytic therapy. Nonetheless, it can be a life-saving therapy in properly selected patients.